'Different Animals With Different Purposes': Putting PRIME And Adaptive Pathways In Context
This article was originally published in SRA
Working out where the new priority medicines scheme that the European Medicines Agency is planning to launch early next year sits with the different regulatory initiatives the agency is promoting is no easy matter.
You may also be interested in...
The EU product information for Ibrance, Verzenios and Kisqali is being updated to include interstitial lung disease and pneumonitis. The change has already been implemented in the US.